详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

6| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究负责人：

研究参与人：

研究单位： [1]Sichuan Baili Pharmaceutical Co., Ltd. [2]Ruijin Hospital, Shanghai Jiaotong University School of Medicine Recruiting Shanghai, Shanghai, China, 200025 [3]SystImmune Inc. [4]Guangzhou First People''s Hospital,Guangzhou,Guangdong,China [5]Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China [6]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China [7]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,Hubei,China [8]Shengjing Hospital of China Medical University,Shenyang,Liaoning,China [9]The Second People''s Hospital of Yibin,Yibin,Sichuang,China

关键词： Relapsed/Refractory Acute B-lymphoblastic Leukemia Relapsed/Refractory Acute Myeloid Leukemia

研究目的：

In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.